Trial results for tofacitinib in immune skin conditions associated with Down syndrome were posted on ClinicalTrials.gov on 2025-12-11. The Phase 2 study reported 0 serious adverse events definitely related to treatment and a mean reduction of -8.41 in whole blood transcriptome interferon (IFN) score at 16 weeks.
Background
People with Down syndrome (DS) often display widespread immune dysregulation, including several immune skin conditions. This study investigated tofacitinib, an FDA-approved drug known to block interferon (IFN) signaling, as a potential treatment for these associated skin conditions.
Trial design
The study (NCT04246372) was a Phase 2 trial that enrolled 47 adolescents and adults with Down syndrome and an autoimmune and/or autoinflammatory skin condition. Conditions investigated included Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, and Vitiligo. The study evaluated the safety and efficacy of tofacitinib treatment.
Key results
The trial reported 0 serious adverse events (SAE) definitely related to tofacitinib treatment. Efficacy outcomes at 16 weeks showed several improvements:
- Whole Blood Transcriptome Interferon (IFN) Score: Mean change of -8.41. An analysis showed an effect size (Cohen's d) of -0.84 (p-value 6.21e-06).
- Investigator's Global Assessment (IGA): Mean change of -1.31. An analysis showed an effect size (Cohen's d) of -0.91 (p-value 6.1e-07).
- Dermatology Life Quality Index (DLQI): Mean change of -2.88. An analysis showed an effect size (Cohen's d) of -1.03 (p-value 4e-08).
- Severity of Alopecia Tool (SALT) Score in participants with alopecia: Mean change of -28.10. An analysis showed an effect size (Cohen's d) of -1.14 (p-value 3.93e-05).
- Modified Sartorius Score (MSS) in participants with hidradenitis suppurativa: Mean change of -19.56. An analysis showed an effect size (Cohen's d) of -0.67 (p-value 0.00399).
- Psoriasis Area and Severity Index (PASI) Score in participants with psoriasis: Mean change of -7.3. An analysis showed an effect size (Cohen's d) of -3.04 (p-value 0.146).
- A Composite Cytokine Score: Mean change of -2.15.
What this means
The results suggest that tofacitinib is well-tolerated in adolescents and adults with Down syndrome, with no serious adverse events definitely related to treatment. The significant reduction in interferon signaling, alongside improvements in multiple clinical scores for various immune skin conditions, indicates that targeting IFN pathways with tofacitinib could be a promising therapeutic strategy for this patient population.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04246372, titled "Tofacitinib for Immune Skin Conditions in Down Syndrome," were posted on 2025-12-11 on clinicaltrials.gov.